Clinical features and therapeutic effect of 15 mantle cell lymphoma patients
10.7644/j.issn.1674-9960.2015.11.012
- VernacularTitle:套细胞淋巴瘤15例临床特征及疗效观察
- Author:
Xiubin XIAO
;
Kaili ZHONG
;
Sihua ZHAO
;
Yun LU
;
Yong DA
;
Yi MA
;
Jing LIU
;
Xilin CHEN
;
Weijing ZHANG
;
Hang SU
- Publication Type:Journal Article
- Keywords:
mantle cell lymphoma;
chemotherapy,adjuvant;
prognosis;
Ki-67 antigen
- From:
Military Medical Sciences
2015;(11):859-862
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical characteristics and recent curative effect of mantle cell lymphoma (MCL) after conventional treatment.Methods Clinical data of 15 MCL patients admitted in the Affiliated Hospital of Academy of Military Medical Sciences between August 2004 and October 2013 were retrospectively analyzed.Results The median age of those patients was 59 and the male to female ratio was 1.5∶1.Fourteen(93%)cases were in Ann-Arbor stages Ⅲ -Ⅳ, 15 cases (100%)primarily with lymph node involvement,7 cases (47%)with bone marrow involvement,4 cases (27%)with gastrointestinal involvement,and 3 cases (20%)with orbit involvement.Less than 40% expression of Ki-67 was observed in 9 cases (60%),while 6 cases were with more than 40% (40%).One case was blastic variant.First-line therapy was CHOP-like regimens,which were combined with rituximab in 8 of the 15 cases.In this study,the median survival time was 12 months (3 -64),and the overal response rate was 80%after induction chemotherapy.The current survival of 7 /9 cases with less than 40% expression of Ki-67 was 8 -64 months,2 /6 cases with more than 40% expression of Ki-67 was 8 and 9 months,respectively.Conclusion MCL mostly occurs in older males.Extranodal invasion is common in MCL as an aggressive tumor.The efficacy of traditional chemotherapy is currently limited.Blastic variant or high expression of Ki-67 is an adverse prognostic indicator.
